<DOC>
	<DOC>NCT01254305</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy, safety and tolerability of Levomilnacipran ER for the treatment of fatigue associated with major depressive disorder (MDD).</brief_summary>
	<brief_title>Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Men and women, 1865 years old Currently meet Diagnostic and Statistical Manual of Mental Disorders, Fourth EditionText Revision (DSMIVTR) criteria for Major Depressive Disorder The patient's current depressive episode must be at least 4 weeks in duration Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control Patients with a history of meeting DSMIVTR criteria for: 1. any manic or hypomanic episode; 2. schizophrenia or any other psychotic disorder; 3. obsessivecompulsive disorder. Patients who are considered a suicide risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Depression</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>